Amlan’s own Dr. Aldo Rossi recently sat down with The Poultry Site at IPPE to discuss the link between optimized feed efficiency and production economics. In the interview, Dr. Rossi explains how subclinical challenges and toxins commonly present in poultry feed can directly erode margins, and how implementing a robust management strategy to address these risks can help producers protect profitability. Maintaining a healthy gut is critical to maximizing nutrient utilization and improving growth performance in commercial poultry operations. To watch the full interview, click here.
The control of pathogens and disease is a recurring challenge for livestock and poultry producers, whether they use conventional or antibiotic-free production systems. Amlan is tackling the challenge of disease prevention with the development of a natural feed additive that combines multiple feed ingredients that help reduce bacterial pathogens and their toxins. NeutraPath®, a natural feed additive for all species, reduces the pathogenic bacterial load and colonization, while also improving intestinal health and structural integrity, all of which contribute to improved bird performance and production economics.
NeutraPath (available in select international markets) features a unique blend of essential oils, fatty acids and Amlan’s proprietary mineral technology. The product’s potent antibacterial formula was engineered to neutralize bacterial toxins, destabilize bacterial cell membranes and disrupt cell-to-cell communication between pathogenic bacteria, all while also improving intestinal health.
NeutraPath has been shown in various studies to have antibacterial properties against a variety of gram-negative and gram-positive bacterial pathogens. By reducing pathogenic bacterial intestinal colonization, NeutraPath improved feed conversion and intestinal health and reduced bacterial diarrhea, necrotic enteritis lesions, and mortality. Here we present a summary of some of the NeutraPath research, including data published in peer reviewed journals or presented at international scientific meetings. Contact info@amlan.com for more details of these studies.
Dual Effects: Disarming Pathogens and Reducing Their Prevalence The antibacterial activity of NeutraPath against a variety of production-limiting pathogen species was demonstrated in both poultry and swine studies. In various broiler studies, birds challenged with either Salmonella enterica serovar Heidelberg, Salmonella enterica serovar Typhimurium or Clostridium perfringens had decreased prevalence and bacterial load of the pathogen in the ceca, cecal tonsils, cecal contents or cloacal swabs compared with the challenged control. There was also a fourfold reduction of alpha-toxin levels in the cecal contents of broilers challenged with C. perfringens compared with the challenged control (Figure 1).
Figure 1: Alpha-toxin levels in the cecal contents of broilers challenged with C. perfringens. Source: Southern Poultry Research, Inc., Athens, GA. 128 total birds.
In swine orally inoculated with F18+ enterotoxigenic E. coli (ETEC), feeding NeutraPath reduced the frequency of diarrhea, indicating a greater resistance to disease (He et al., 2022). Changes in the fecal microbiome and ileal mucosa microbiota composition suggested NeutraPath also helps maintain a desirable balance in the intestinal microbial ecosystem.
Collectively, these studies indicate that NeutraPath can selectively modulate gut microbiota homeostasis via exerting potent antibacterial effects against enteric pathogenic bacteria while preserving or promoting beneficial bacteria.
Healthier Swine and Poultry The antibacterial effects of NeutraPath promote positive health benefits for poultry and swine. In broilers challenged with C. perfringens-induced necrotic enteritis in combination with Eimeria maxima infection, NeutraPath improved livability and necrotic enteritis-related lesion scores compared with challenged control birds (Figure 2). Additionally, using antibiotics instead of NeutraPath produced similar mortality rates and lesion scores as NeutraPath.
Figures 2 and 3: Necrotic enteritis-caused mortality rates and lesion scores in broilers. 240 total birds. Source: Southern Poultry Research, Inc. Athens, GA.
The data from the broiler studies indicate that NeutraPath can be used to help manage C. perfringens-induced necrotic enteritis in broilers. As mentioned earlier, NeutraPath was also shown to decrease the incidence of severe diarrhea in weaned pigs challenged with Enterotoxigenic E. coli (ETEC).
Enhanced Production Performance NeutraPath was also able to improve production parameters in poultry and swine. In a summary of four similarly designed broiler studies that experimentally induced necrotic enteritis, NeutraPath showed better performance than the challenged control group and performed similarly to antibiotic-treated birds (Table 1). The results of these studies show that NeutraPath was comparable to an antibiotic in improving performance of broilers challenged with necrotic enteritis.
Table 1: Comparison of necrotic enteritis-challenged broiler performance. Source: Southern Poultry Research Inc., Athens, GA. Birds were challenged with C. perfringens at 2 weeks of age and grown to day 28.
In the swine ETEC challenge study, compared to the control, pigs fed NeutraPath demonstrated improved growth during the last two weeks of the study with improvements in feed efficiency during days 14 to 21 post-inoculation. These studies demonstrate that NeutraPath can enhance growth performance in broilers and swine challenged with production limiting pathogens.
In these studies, the synergism of NeutraPath ingredients worked well to reduce pathogenic bacterial colonization, improve health parameters and enhance production performance in swine and poultry. For more information on NeutraPath or to set up your own NeutraPath trial, contact info@amlan.com.
We and selected third parties collect personal information as specified in the privacy policy and use cookies or similar technologies for technical purposes and with your consent, for other purposes as specified in the cookie policy.
Denying consent may make required features unavailable. Use the “Accept” button to consent. Use the “Reject” button or close this notice to continue without accepting.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
